Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States

Benner, Joshua S.; Smith, Timothy W.; Petrilla, Allison; Klingman, David; Goel, Sangeeta; Tang, Simon; Wong, Nathan D.

doi:10.1016/j.jash.2007.07.001

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MRFs can be elaborated to include sedentary lifestyle, unhealthy dietary behavior low socioeconomic level, regular alcohol consumption, urbanization, and pollution [ 16 , 17a – 17c ]. Different studies stated that these modifiable RFs are related to a large number of premature CV deaths globally [ 18 , 19 ]. In this study, CVDs RFs prevalence results demonstrated similar results of a study performed in Africa and the Middle East (AfME) region [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of cardiovascular Diseases Risk Factors Among Jordanians

Alsaud¹,

Tabbaa²,

Kasabri³

et al. 2020

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

Background and aims One of the most common causes of death worldwide is cardiovascular diseases (CVDs). This study evaluated the prevalence of CVDs risk factors (RFs) and their constellation electively among the Jordanian population and, assessing the most prevalent RF interplay with the rest of CVDs RFs as well as the impact of age and gender dimorphism on the frequencies of coexistence of multiple CVDs risk factors (RFs) among the Jordanian population. Methods and results In this observational multicenter study, a total of 1449 subjects were enrolled. The mean age (±SD) was 44.35 ± 14.46 years; 796 (54.9%) of them were females and 801 (55.28%) of the whole study pool had no family history of premature CVDs. Only 5.9% of the population did not have any of these RFs. The prevalence of CVDs MRFs within-affected subjects was as follows: there were 1081 (74.6%) subjects with overall dyslipidemia, 471 (32.51%) with obesity, 456 (31.47%) were smokers, and at the first diagnostic encounter 541 (37.47%) were with elevated blood pressure and, 310 (21.51%) were with elevated random blood sugar. The coexistence of ≥ two, ≥ three and, ≥ four RFs was observed in 75.7%, 44.4%, and 21.4% of the subjects, respectively. The constellation of multiple RFs was more frequent in men than that in women, where the presence of ≥ two RFs for men was at 86.18% vs. 67.09% for women. Similarly, the appearance of multiple RFs increases with age, starting from the existence of ≥ three, and four RFs respectively. Most notably the clustering of ≥ five RFs in the age group of 45–59 years showed the greatest frequency vs. any other age group. Conclusions CVDs risk factors (RFs) and clusters of them are extremely prevalent in the Jordanian population. Overall dyslipidemia is the most prevalent MRF and the most favors clustering with other CVDs RFs. Combined two RFs had the highest proportional frequency between all six RFs clusters. The constellation of at least two, three, and four CVDs RFs presented at almost three-fourth, half, and around one-fourth; respectively, Middle-aged males presented significantly higher rates of ≥ five RFs occurrences than females.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of cardiovascular Diseases Risk Factors Among Jordanians

Alsaud¹,

Tabbaa²,

Kasabri³

et al. 2020

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

show abstract

“…The authors chose to select a similar patient type to those who participated in the ASCOT-LLA trial, which demonstrated that the addition of atorvastatin to an amlodipine-based antihypertensive regimen lead to improved clinical outcomes in this patient type 3,17 . Furthermore as a group, patients at moderate CV risk are likely to have the greatest number of CV events during the next 10 years due to the large number of patients with this risk profile [27][28][29][30] . Therefore, given the high prevalence of this particular patient group, treating these individuals would have a large impact on the total burden of CVD.…”

Section: Discussionmentioning

confidence: 99%

Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial

Zamorano

Erdine

Pavía

et al. 2011

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Hypertension is one of the most important reasons for atherosclerosis, myocardial infarction, and left ventricular hypertrophy [7,8]. The metabolic pathway of rennin-angiotensin plays a role in controlling blood pressure.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the in vivo antihypertensive effect and antioxidant activity of HL-7 and HL-10 peptide in mice

2021

View full text Add to dashboard Cite

In this study, the in vivo antioxidant and antihypertensive properties of peptides HL-7 with the sequence of YLYELR and HL-10 with the sequence of AFPYYGHHLG were identi ed from scorpion venom of H. lepturus were evaluated. To study the in vivo effects of peptides, D-galactose-induced and DOCA saltinduced mice models were used. The results of the antioxidant assay for both peptides showed that the activity of serum and liver catalase (CAT), as well as superoxide dismutase (SOD) enzymes, was signi cantly decreased in the D-galactose-induced group (NC), while MDA levels were increased in serum and the liver tissue samples (p<0.01). Compared with the D-galactose-induced mice, the peptide treated mice group had a higher activity of antioxidant enzymes namely CAT and SOD, as well as a lower lipid peroxidation level. Also, the results of antihypertensive activity for both peptides showed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the mice treated with the HL-7 and HL-10 peptides were signi cantly reduced in a dose-dependent manner (p<0.01). The administration of the HL-7 peptide at doses of 5 mg/kg BW (LP1) and 15 mg/kg BW (HP1) signi cantly diminished the mean arterial blood pressure (MAP) by 31 mmHg and 40.47 mmHg, respectively. Accordingly, treatment of mice with the HL-10 peptide at doses of 5 mg/kg BW (LP2) and 15 mg/kg BW (HP2) considerably lowered the MAP by 18.3 mmHg and 21.93 mmHg, respectively. Our ndings suggest that both the HL-7 and HL-10 peptides could be potentially utilized as antihypertensive and antioxidant components.

show abstract

Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States

Cited by 6 publications

References 17 publications

Prevalence of cardiovascular Diseases Risk Factors Among Jordanians

Prevalence of cardiovascular Diseases Risk Factors Among Jordanians

Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial

Evaluation of the in vivo antihypertensive effect and antioxidant activity of HL-7 and HL-10 peptide in mice

Contact Info

Product

Resources

About